Opko Health (NASDAQ:OPK)‘s stock had its “buy” rating restated by equities researchers at Barrington Research in a report issued on Monday, November 12th. They presently have a $7.00 target price on the biotechnology company’s stock. Barrington Research’s price objective would suggest a potential upside of 115.38% from the stock’s previous close. Barrington Research also issued estimates for Opko Health’s FY2018 earnings at ($0.20) EPS, Q1 2019 earnings at ($0.05) EPS, Q2 2019 earnings at ($0.04) EPS, Q3 2019 earnings at ($0.04) EPS, FY2019 earnings at ($0.17) EPS, FY2020 earnings at ($0.02) EPS, FY2021 earnings at $0.11 EPS and FY2022 earnings at $0.31 EPS.
The analysts wrote, “We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline.””
Several other brokerages have also recently issued reports on OPK. BidaskClub upgraded Opko Health from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 3rd. Cantor Fitzgerald reissued a “buy” rating and set a $20.00 target price on shares of Opko Health in a research report on Tuesday, August 7th. Finally, ValuEngine raised Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $9.50.
Shares of OPK traded down $0.24 during midday trading on Monday, reaching $3.25. The company had a trading volume of 6,506,000 shares, compared to its average volume of 5,378,512. The company has a market capitalization of $1.95 billion, a PE ratio of -11.07 and a beta of 1.90. The company has a quick ratio of 0.78, a current ratio of 0.91 and a debt-to-equity ratio of 0.03. Opko Health has a 1-year low of $2.66 and a 1-year high of $6.40.
Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Opko Health had a negative return on equity of 8.68% and a negative net margin of 30.24%. The business had revenue of $250.00 million during the quarter, compared to analysts’ expectations of $264.04 million. During the same period in the prior year, the business posted ($0.08) EPS. The company’s revenue was up 1.6% compared to the same quarter last year. As a group, equities analysts anticipate that Opko Health will post -0.21 earnings per share for the current fiscal year.
In related news, CEO Phillip Md Et Al Frost bought 10,000 shares of the company’s stock in a transaction dated Friday, September 7th. The shares were acquired at an average price of $5.57 per share, with a total value of $55,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 42.74% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. boosted its position in Opko Health by 1,290.1% during the third quarter. Meeder Asset Management Inc. now owns 31,611 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 29,337 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Opko Health during the second quarter worth $136,000. North Star Investment Management Corp. purchased a new stake in Opko Health during the second quarter worth $141,000. RPg Family Wealth Advisory LLC raised its holdings in shares of Opko Health by 74.3% in the second quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 13,250 shares during the last quarter. Finally, Xact Kapitalforvaltning AB raised its holdings in shares of Opko Health by 58.2% in the first quarter. Xact Kapitalforvaltning AB now owns 57,921 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 21,300 shares during the last quarter. Hedge funds and other institutional investors own 26.20% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Story: How to invest in a bear market
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.